EU and US could reach trade deal this weekend - Reuters
MAINZ, Germany - BioNTech SE (NASDAQ:BNTX) reported better-than-expected fourth quarter results on Monday.
The company’s stock dropped 3.46% in premarket trading following the earnings release.
The German biotech company posted Q4 earnings per share of €1.08, beating analyst estimates. Revenue came in at €1.19 billion, surpassing the consensus forecast of €1.12 billion.
However, BioNTech’s 2025 revenue guidance of €1.7-2.2 billion fell short of market expectations, reflecting declining demand for its COVID-19 vaccines.
For the full year 2024, BioNTech reported a net loss of €665.3 million, or €2.77 per share, compared to a profit of €930.3 million, or €3.83 per share, in 2023. Full year revenue declined to €2.75 billion from €3.82 billion the previous year.
"In 2024, we made significant progress towards our vision through important oncology pipeline advancements," said CEO Ugur Sahin. He added that the company expects 2025 to be "a data-rich year with multiple important updates from our priority programs."
BioNTech ended 2024 with €17.4 billion in cash and investments. The company plans to continue investing heavily in R&D, guiding for €2.6-2.8 billion in R&D expenses for 2025.
While COVID-19 vaccine sales are declining, BioNTech is advancing its oncology pipeline, with over 20 ongoing Phase 2 and 3 clinical trials. The company expects its first oncology product launch in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.